CN1109745A - Ibuprofen-containing solid composition - Google Patents
Ibuprofen-containing solid composition Download PDFInfo
- Publication number
- CN1109745A CN1109745A CN94112789A CN94112789A CN1109745A CN 1109745 A CN1109745 A CN 1109745A CN 94112789 A CN94112789 A CN 94112789A CN 94112789 A CN94112789 A CN 94112789A CN 1109745 A CN1109745 A CN 1109745A
- Authority
- CN
- China
- Prior art keywords
- ibuprofen
- granule
- particle
- polymerizable compound
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a water insoluble polymeric compound which comprises a core including brufen and covers the surface of the core including brufen, and a solid combination including the brufen which belongs to the sugar alcohol or sugar class and covers the surface of the water insoluble polymeric compound. The combination effectively restrains the irritative bitterness and the sublimation of the brufen, and the continuous shielding effect is displayed, and the invention is stable within a period of time, and any change such as the wetness, the solidifying and the discoloration is inexistent.
Description
The present invention relates to a kind of ibuprofen that contains, and can suppress the zest bitterness and the stable in time solid composite of ibuprofen, and relate to its preparation method.
Ibuprofen, 2-(4-isobutylphenyl) propanoic acid has antiinflammatory, brings down a fever and analgesic effect, and is widely used as medicine.Yet, have the oral difficult problem that contains ibuprofen pharmaceutical of a lot of relevant preparations.
One of these difficult problems are to suppress the method for the zest bitterness of ibuprofen.Because this zest bitterness much contains ibuprofen pharmaceutical and is made to capsule or tablet (tablet that thin film coats, the tablet that steamed bun stuffed with sugar covers).Almost there is not ibuprofen granule, as the preparation of particle, fine particle and powder.
Recommended certain methods in the effort of the zest bitterness of the ibuprofen in suppressing granular preparation: the method for adding aluminum hydroxide (Japanese Patent Laid open (Kokai) No.101321/1988) prepares the method for particle and fine particle etc. with ibuprofen with the soluble polymerizable compound kneading of stomach.Effort on these methods is still not enough.
Another problem relevant with containing ibuprofen pharmaceutical is the fusing point of ibuprofen low (75-77 ℃).Ibuprofen can distil in a period of time, and this can cause the decline of masking effect and cause change such as moistening, curing and discoloration.Particularly Motrin contain can influence ibuprofen or by the situation of the chemical compound that ibuprofen influenced under, do not show effect of sufficient for preventing that particle that this class changes from separating.Add solidified protection agent commonly used, as light anhydrous silicic acid (Adosolider 101, Aerosil 200 etc.) or the anti-moistening of Talcum or general time solidify almost do not show any to containing the effect of ibuprofen solid preparation.
Therefore, never can overcome the above-mentioned solution that contains an ibuprofen solid preparation aspect difficult problem effectively.Granular product, as particle, microgranule and powder are widely used in common medicine and medical because its advantage, as brilliance with mixcibility mutually other powder and be convenient to be made into medicine.This goods form is inapplicable to ibuprofen to be inconvenient.
Except that these advantages, granule can be made to other preparation, as capsule and tablet.This is another reason that expectation contains the solid preparation of ibuprofen.
Therefore, the purpose of this invention is to provide a kind of solid preparation that contains ibuprofen, it can suppress ibuprofen the zest bitterness, be easy to compounding pharmaceutical, and in the general time, be stable.
The inventor has done research completely, so that finish above-mentioned purpose, and find that the insoluble polymerizable compound of water coats and contain the solid preparation that contains ibuprofen as the core system of the ibuprofen of active ingredient, the layer that forms a kind of sugar alcohol or saccharide then in its surface can suppress the zest bitterness and the distillation of ibuprofen effectively, and has lasting screening effect.In addition, find that this preparation is stable in a period of time, and do not have any variation such as moistening, curing and variable color.
The inventor finds that again this solid preparation that contains ibuprofen also can be used as the raw material of capsule and tablet owing to its advantage.
Therefore, first purpose of the present invention provides a kind of solid composite that contains ibuprofen, it comprises the granule that contains ibuprofen, a kind of water-insoluble polymerizable compound, and a kind of sugar alcohol or saccharide, wherein said water-insoluble polymerizable compound is coated on the described particulate surface that contains ibuprofen, and described sugar alcohol or saccharide then are coated on the clad surface of described water-insoluble polymerizable compound.
Second purpose of the present invention provides the method that preparation contains the solid composite of ibuprofen, and it comprises:
Coat the granule that contains ibuprofen with water-insoluble polymerizable compound, and
Coat the clad surface of described water-insoluble polymerizable compound with sugar alcohol or saccharide.
The present invention other and further purpose, performance and advantage will become clearer from following statement.
For preparing the solid composite that contains ibuprofen of the present invention, at first coat the particulate surface that contains ibuprofen with water-insoluble polymerizable compound.
Preparation is had no particular limits by the particulate method that contains ibuprofen that the core of compositions of the present invention constitutes.The prilling process commonly used of any preparation particle as stirring-granulating, the pelletize of fluidised form layer, uses the dried pelletize and the extruder grain of roll-type comminutor all can adopt.Wherein particularly preferably being to provide clearly that the extruder grain of particle size distribution all can adopt.Wherein particularly preferably being to provide the extruder grain method of particle size distribution clearly.This particle size can be the size of any scope, because it drops in the normal range of particle, fine particle and powder, and preferred range is the 30-42 order.
There is not any particular restriction for the insoluble polymerizable compound of this water that is coated on this granule, as long as it is the same chemical compound that is generally used for medication preparation.Ethyl cellulose and acrylic polymer are preferred.Particularly preferred commercially available prod comprises the aqueous dispersion of ethyl cellulose, as " Aquacoat " (trade mark, Asahi Chemical Industries makes) and " Surelease " (trade mark, Nippon Calacone makes); The aqueous dispersion of aminoalkyl methacrylate ester copolymer RS is as " Eudragit RS30D " (trade mark, R ō hm Pharma makes); And the dispersion of methyl methacrylate-ethyl acrylate copolymer, as " Eudragit NE 30D " (trade mark, R ō hm Pharma makes).
The consumption that coats the insoluble polymerizable compound of this particulate water is the 2-10%(weight that contains the core of ibuprofen granule), 3-5%(weight preferably) (hereinafter being reduced to %).Coating available common fluid layer comminutor, roll-type fluid layer comminutor or centrifugal roll-type comminutor carries out.
The granule that contains ibuprofen that the surface insoluble polymerizable compound of water coats further is coated with sugar alcohol or saccharide subsequently and forms a layer.
Sugar alcohol that provides as an example or saccharide are D-mannitol, xylitol, sorbitol, refined sugar, lactose, glucose, reduction maltose etc.
The sugar alcohol of these coatings or the consumption of saccharide are the 2-20% that contains the ibuprofen granule core, and better is 5-10%.Coating can be conventional method, use fluid layer granulation machine, roll-type fluid layer granulation machine or centrifugal roll-type granulation machine to carry out.
Therefore, the insoluble polymerizable compound of described water can contain hydrophobic material, as Talcum, or plasticizer-containing, as fatty acid glyceride, and described sugar alcohol or saccharide coating can contain the composition that spice, coloring agent, sweetener etc. are generally used for medicine.
The solid preparation of making like this that contains ibuprofen can its form as granular preparation, is used as particulate or particle.Can be made into the solid preparation of other type, as the tablet that it is filled in the capsule preparations in the capsule or its mold pressing is formed.
The crested in the solid preparation that contains ibuprofen of the present invention of the zest bitterness of ibuprofen.In addition, it is easy to administration, because this solid preparation is not with its inherent coarse preparation that is coated of feeling to give.And then, because it does not have electrostatic characteristic, so it is easy to control.In addition, it prevents that in an ability that suppresses the ibuprofen distillation in long-time this granule is wetted, solidifies or decolours, and keep its stability in a period of time.When the medicine that influences the ibuprofen performance, be effective especially when being mixed together as ascorbic acid, chloroaniline maleate or methyl Herba Ephedrae quinoline hydrochloride (methylephedoline hydrochloride).
Other characteristics of the present invention will state below in the process of illustrative embodiment and become clearly that these embodiments are used to illustrate the present invention, but unintentionally it are limited to some extent.
Embodiment 1
(1) a vertical granulator; the FM-VG-25(trade mark; Paulec Co. makes) middle 1800g ibuprofen, 2240g refined sugar, 288g crystalline cellulose (" AVICEL PH101 " trade mark of mixing; Asahi Chemical Industries makes); 320g corn starch and 112g hydroxypropyl cellulose (HPC-L trade mark, Nippon Soda makes).After interpolation 500g contains the pure water of 40g polyoxyl-40-stearate (MYS-40); this mixture of kneading is also used two arch glan TDG-110 type comminutor (trade marks; Fuji Powdal Co. makes, mesh size: 0.4mm φ, thickness: 0.4mm) pelletize.Particle is at fluidised form type Glat WSG-5(trade mark: ohkawara Manufacturing Co. makes) in dry, reuse 30 orders and the 42 mesh sieve result that sieves obtains the granule that contains ibuprofen that particle size is pushed for the 32-42 purpose.
(2) granule of gained is coated with the clad material of following prescription with fluidised form type Glat WSG-5, its consumption be make the amount of Aquacoat be this particulate 5%.
＜prescription 〉
Aquacoat（Asahi Chemical Industries） 26.3%
Talcum 4.5%
Fatty acid glyceride (Mybaset 9-45) 2.6%
Pure water 66.6%
Total amount 100.0%
Then, the aqueous solution of the D-mannitol with 20% spray is all over the granule of above-mentioned gained, and the amount that its amount will make the D-mannitol is particulate 5% for this, and then with this particle drying, the result obtains containing the particle of ibuprofen.
Embodiment 2
Prepare the granule that contains ibuprofen by the mode identical, with the clad material of following prescription, it coated then with fluidised form type Glat WSG-5 with embodiment 1＜1 〉, its amount amount of " Eudragit NE30D " that will make be this particulate 3%.
＜prescription 〉
Eudragit NE30D（Rōhm Pharma） 26.3%
Talcum 4.5%
Fatty acid glyceride (Mybaset 9-45) 2.6%
Pure water 66.6%
Total amount 100.0%
Then with 20% D-mannitol aqueous solution all over spraying the granule of stating gained, the amount that its consumption will make the D-mannitol is for should be particulate 5%, this granule of drying then, the result obtains containing the particle of ibuprofen.
Embodiment 3
By and embodiment 1(1) in identical mode prepare the granule that contains ibuprofen, with the clad material of following prescription, it is coated then with fluidised form type Glat WSG-5, material usage to make the amount of " Eudragit RS30D " be this particulate 5%.
＜prescription 〉
Eudragit NE30D（Rōhm Pharma） 26.3%
Talcum 4.5%
Triethyl citrate 2.6%
Pure water 66.6%
Total amount 100.0%
Then, with the granule of 20% lactose aqueous solution spray all over above-mentioned gained, the amount that its amount will make lactose is particulate 5% for this, and then with this particle drying, the result obtains containing the particle of ibuprofen.
Embodiment 4
By with embodiment 1＜1〉in identical mode prepare the granule that contains ibuprofen, the clad material of the following prescription of reuse, Glat-WSG-5 coats it with the fluidised form type, and the consumption of material will make Surelease(Nippon Calacone) amount for this particulate 5%.
＜prescription 〉
Surelease（Nippon Calacone） 26.3%
Talcum 4.5%
Fatty acid glyceride (Mybaset 9-45) 2.6%
Pure water 66.6%
Total amount 100.0%
Then with the granule of 20% D-mannitol spray all over above-mentioned gained, its amount will make the amount of D-mannitol particulate for this reason 5%, and with this particle drying, the result obtains containing the particle of ibuprofen.
Embodiment 5
By and embodiment 1(1) identical mode prepares the granule that contains ibuprofen, the clad material of the following prescription of reuse coats it with fluidised form type Glat WSG-5, material usage will make the amount particulate for this reason 8% of ethyl cellulose.
＜prescription 〉
Ethyl cellulose (N-10-F, Shin-etsu
Chemical Industies） 6.85%
Sodium laurylsulfate 0.71%
Hexadecanol 0.32%
Fatty acid glyceride (Mybaset 9-45) 2.62%
Talcum 4.5%
Pure water 85.0%
Total amount 100.0%
Then, 20% refined sugar aqueous solution is sprayed the granule of above-mentioned gained, its amount will make the amount of refined sugar particulate for this reason 10%, dry then this granule, and the result obtains containing the particle of ibuprofen.
Comparative Examples 1
By and embodiment 1(1) in identical mode prepare the granule that contains ibuprofen, then with the clad material of following prescription, with fluidised form type Glat WSG-5 it is coated, the amount of material to make the amount of polyvinyl acetal lignocaine acetas and hydroxypropyl cellulose be respectively this particulate 5%.
＜prescription 〉
Polyvinyl acetal lignocaine acetas
(AEA, Sankyo Co. makes) 2.5%
Hydroxypropyl cellulose
(HPC-SL, Nippon Soda makes) 2.5%
Alcohol 95 .0%
Total amount 100.0%
Comparative Examples 2
By and embodiment 1(1) identical mode prepares the granule that contains ibuprofen, uses the clad material of following prescription then, with fluidised form type Glat WSG-5 it is coated, material usage to make the amount of " Aquacoat " be this particulate 5%.
＜prescription 〉
Aquacoat （Asahi Chemical Industries） 26.5%
Talcum 4.5%
Fatty acid glyceride (Mybaset 9-45) 2.6%
Pure water 65.4%
Total amount 100.0%
Comparative Examples 3
In the granule of Comparative Examples 2, add Adosolider 101(0.2% again) and Talcum (0.5%).
Comparative Examples 4
By and embodiment 1(1) in identical mode prepare the granule that contains ibuprofen, use the clad material of following prescription then, with fluidised form type Glat WSG-5 it is coated, material usage to make the amount of " Aquacoat " be this particulate 5%.
Aquacoat（Asahi Chemical Industries） 26.5%
Talcum 4.5%
Fatty acid glyceride (Mybaset 9-45) 2.6%
Pure water 65.4%
Total amount 100.0%
Then, the hydroxypropyl cellulose with 5% (HPC-SL) alcoholic solution is sprayed on the granule of above-mentioned gained, and the amount that make HPC-SL is for should be particulate 10%, this granule of drying then, and the result obtains containing the granule of ibuprofen.
Test example 1
With the granule of aluminothermy packing gained in embodiment 1-5 and Comparative Examples 1-4, then it was stored one month in 50 ℃ thermostat.With this sample test cover, wettability/curing and discoloration.The results are shown in table 1.
Table 1
Store back (50 ℃, month) in the preparation
Covering property wettability/covering property of curing wettability/curing allochroic
Embodiment
1 good the confirmation well confirms to confirm
2 good confirmations well confirm to confirm
3 good confirmations well confirm to confirm
4 good confirmations well confirm to confirm
5 good confirmations well confirm to confirm
Comparative Examples
1 does not badly confirm bad confirmation flavescence
2 confirm bad confirmation flavescence well
3 do not confirm bad confirmation flavescence well
4 do not confirm bad confirmation flavescence well
The particle that makes among the embodiment 1-5 all shows superior screening effect in the preparation with after storing, and does not have any moistening and curing, and does not present variable color after storage.Otherwise, the product of Comparative Examples 1-4, promptly use the particle (Comparative Examples 1) of the mixture of polymers coating of stomach polymer soluble and water soluble, the particle (Comparative Examples 2) that coats of water insoluble polymer only, add the solidified protection agent, the particle (Comparative Examples 4) that coats and be covered with in its surface the water soluble polymeric layer as Adosolider 101 and steatitic particle (Comparative Examples 3) and water insoluble polymer shows all that screening effect descends and be wetted in a period of time, solidifies and variable color.
Embodiment 6
Low hydroxypropyl cellulose, 320g corn starch and the 60g hydroxyphenyl cellulose that replaces of chloroaniline maleate, 300g Caffeine Anhydrous, 3762g lactose, 288g that in a vertical granulation machine " FM-VG-25 " (trade mark, Pawlec Co. makes), mixes 30g.After interpolation 900g contains the pure water of the poly-hydroxyl oxygen base ester (MYS-40) of 40g stearic acid-40-, with this mixture kneading, then with two arch glan TDG-110 type granulation machine (sieve diameters: 0.4mm φ, thickness: 0.4mm) granulating.Particle is dry in fluidised form type Glat WSG-5, and reuse 30 orders and 42 mesh sieves sieve, and the result obtains the granule that contain ibuprofen (A) of particle size for the extruding of 30-42 purpose.The granule that contains ibuprofen that obtains among this granule (A) and the embodiment 1 mixed and obtain hybrid particles.
Embodiment 7
The ascorbic acid, 2732g refined sugar, 288g low-substituted hydroxypropyl cellulose, 480g corn starch and the 60g hydroxypropyl cellulose that in a vertical granulation machine FM-VG-25, mix 1200g.After interpolation 300g contains the pure water of the poly-hydroxyl oxygen base ester (MYS-40) of 40g stearic acid-40-, with this mixture kneading, the two arch of reuse glan TDG-110 comminutor (sieve diameters: 0.4mm φ, thickness: 0.4mm) granulating.In fluidised form type Glat WSG-5, make the particle drying, reuse 30 orders and the screening of 42 mesh sieves, the result obtains the granule that contain ibuprofen (B) of particle size for the extruding of 30-42 purpose.With granule (B) with mix by the made granule of embodiment 1 and obtain hybrid particles.
Embodiment 8
With the granule that contains ibuprofen (A) that makes in embodiment 6 and 7 and (B) mix with the prepared granule that contains ibuprofen among the embodiment 1 respectively and obtain hybrid particles.
Comparative Examples 5
The granule that contains ibuprofen (A) that makes among the embodiment 6 is mixed with the prepared granule that contains ibuprofen in Comparative Examples 3 and obtain hybrid particles.
Comparative Examples 6
The granule that contains ibuprofen that makes in the granule that contains ibuprofen (B) that makes among the embodiment 7 and the Comparative Examples 3 is mixed and obtain hybrid particles.
Comparative Examples 7
With the granule that contains ibuprofen (A) that makes in embodiment 6 and 7 and (B) mix with the prepared granule that contains ibuprofen in the Comparative Examples 1 respectively and obtain hybrid particles.
Test example 2
With the hybrid particles that derives from embodiment 6-8 and Comparative Examples 5-7 with the aluminothermy packing from, in 50 ℃ of thermostats, deposited one month.To these samples do to cover, wettability/curings and variable color test.The results are shown in table 2.
Table 2
Deposit back (50 ℃, month) in the preparation
Wettability/curing wettability/curing decolouring
Embodiment
6 do not confirm not confirm not confirm
7 do not confirm not confirm not confirm
8 do not confirm not confirm not confirm
Comparative Examples
5 do not confirm wetted flavescence
6 do not confirm wetted browning
7 do not confirm wettability/curing browning
In the granule of embodiment 6-8, confirm no wettability, curing and variable color, but whole granules of Comparative Examples 5-7 all show some wettability, curing and variable color.
Embodiment 9
At V-Mixer (V-10: trade mark, Tokuju Kosakusho Co. manufacturing) the made granule that contains ibuprofen among the fusion 1320g embodiment 1 in, 780g lactose crystal (80M: trade mark, Die Melkindustrie Veghel), 100g Croscarmellose sodium (AC-Di-Sol: trade mark, Asahi Chemical Industries makes), 25g Talcum and 25g magnesium stearate, use single-stroke pelleter (N-30E: trade mark then, Okada Seisakusho Co. manufacturing) makes tablet, the tablet that the result obtains, every heavy 250mg, thick 3.4mm, diameter 9mm.
Embodiment 10
Made granule that contains ibuprofen and 60g light anhydrous silicic acid in fusion 2640g embodiment 1 in the V-type mixer (V-10: trade mark, Tokuju, Kosakusho Co. manufacturing), the reuse capsule filling machine makes 1
#Capsule.Each capsule contains this kind of 450mg mixture.
Clearly by above-mentioned guidance, a large amount of modifications and variations of the present invention all are possible.Therefore it being understood that in the scope of appended claim except that stating especially, the present invention is enforceable herein.
Claims (6)
1, a kind of solid composite that contains ibuprofen that contains ibuprofen granule, water-insoluble polymerizable compound and sugar alcohol or saccharide that comprises, the insoluble polymerizable compound of wherein said water is coated on the described particulate surface that contains ibuprofen, and described sugar alcohol or saccharide are coated on the clad surface of described water-insoluble polymerizable compound.
2, the solid composite that contains ibuprofen of claim 1, the amount of the water-insoluble polymerizable compound of wherein said coated particle is a 2-10%(weight).
3, the solid composite that contains ibuprofen of claim 1, the sugar alcohol of wherein said coating or the amount of saccharide are the 2-20%(weight of this particle cores that contains ibuprofen).
4, the solid composite that contains ibuprofen of claim 1, it is fine particle, particle, capsule or tablet.
5, preparation contains the method for the solid composite of ibuprofen, and it comprises:
Coat the granule that contains ibuprofen with water-insoluble polymerizable compound, and
Coat the clad surface of the insoluble polymerizable compound of described water with sugar alcohol or saccharide.
6, comprise the solid composite that contains ibuprofen of claim 1 definition and contain the pharmaceutical composition of the solid composite that is selected from the medicine in the thing group of being formed by ascorbic acid, chloroaniline maleate and methyl Herba Ephedrae quinoline hydrochloride.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP318530/93 | 1993-12-17 | ||
| JP5318530A JP2841267B2 (en) | 1993-12-17 | 1993-12-17 | Ibuprofen-containing granules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1109745A true CN1109745A (en) | 1995-10-11 |
| CN1090477C CN1090477C (en) | 2002-09-11 |
Family
ID=18100149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94112789A Expired - Fee Related CN1090477C (en) | 1993-12-17 | 1994-12-17 | Ibuprofen-containing solid composition |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2841267B2 (en) |
| KR (1) | KR100253525B1 (en) |
| CN (1) | CN1090477C (en) |
| TW (1) | TW276994B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100379407C (en) * | 1997-12-19 | 2008-04-09 | 史密丝克莱恩比彻姆公司 | Process for manufacturing bite-dispersion tablets |
| WO2013183062A2 (en) * | 2012-06-05 | 2013-12-12 | Rubicon Research Private Limited | Palatable formulations of ibuprofen |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005035995A (en) * | 2003-07-01 | 2005-02-10 | Sankyo Co Ltd | Ibuprofen-containing oral composition |
| JP4913359B2 (en) * | 2004-05-07 | 2012-04-11 | 第一三共ヘルスケア株式会社 | Ibuprofen-containing pharmaceutical composition |
| JP2012046540A (en) * | 2004-05-07 | 2012-03-08 | Daiichi Sankyo Healthcare Co Ltd | Ibuprofen-containing pharmaceutical composition |
| JP4832045B2 (en) * | 2005-09-28 | 2011-12-07 | ロート製薬株式会社 | Pharmaceutical composition containing mequitazine, ibuprofen and tranexamic acid |
| JP5465824B2 (en) * | 2006-03-24 | 2014-04-09 | 第一三共ヘルスケア株式会社 | Pharmaceutical preparation and method for producing the same |
| JP5527921B2 (en) * | 2006-12-22 | 2014-06-25 | エスエス製薬株式会社 | Oral solid composition concealing bitterness |
| CA2782177C (en) * | 2009-11-30 | 2019-10-15 | Aptalis Pharmatech, Inc. | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
| KR101711876B1 (en) * | 2013-06-17 | 2017-03-03 | 닛뽕소다 가부시키가이샤 | Coating agent containing hydroxyalkyl cellulose |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0297866A3 (en) * | 1987-07-01 | 1989-12-13 | The Boots Company PLC | Therapeutic agents |
-
1993
- 1993-12-17 JP JP5318530A patent/JP2841267B2/en not_active Expired - Fee Related
-
1994
- 1994-12-14 KR KR1019940034202A patent/KR100253525B1/en not_active IP Right Cessation
- 1994-12-16 TW TW083111764A patent/TW276994B/zh active
- 1994-12-17 CN CN94112789A patent/CN1090477C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100379407C (en) * | 1997-12-19 | 2008-04-09 | 史密丝克莱恩比彻姆公司 | Process for manufacturing bite-dispersion tablets |
| WO2013183062A2 (en) * | 2012-06-05 | 2013-12-12 | Rubicon Research Private Limited | Palatable formulations of ibuprofen |
| WO2013183062A3 (en) * | 2012-06-05 | 2014-01-30 | Rubicon Research Private Limited | Palatable formulations of ibuprofen |
Also Published As
| Publication number | Publication date |
|---|---|
| TW276994B (en) | 1996-06-01 |
| JP2841267B2 (en) | 1998-12-24 |
| CN1090477C (en) | 2002-09-11 |
| KR950016718A (en) | 1995-07-20 |
| KR100253525B1 (en) | 2000-05-01 |
| JPH07173057A (en) | 1995-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1025283C (en) | New drug preparation | |
| CN1108791C (en) | Galenic formula with extended release of milnacipran | |
| CN100341493C (en) | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | |
| CN1201732C (en) | Oral pharmaceutical forms of administration with a delayed action | |
| CN1151844C (en) | Preparation of pharmaceutical active granules | |
| CN1247190C (en) | Immediate release tablet cores of insoluble drugs having sustained release coating | |
| CN1023293C (en) | Controlling-release preparation | |
| CN1204885C (en) | Pharmaceutical composition contg. fenofibrate and preparation method | |
| CN1184971C (en) | Pharmaceutical combination preparations | |
| CN1080169A (en) | The controlled release tablet that contains water soluble drug | |
| CN1058533A (en) | Controlled-release pharmaceutical formulation | |
| CN1556697A (en) | Controlled drug delivery systems providing variable release rates | |
| CN1124452A (en) | Process | |
| CN1134666A (en) | Multiple unit tableted dosage form I | |
| SK2762002A3 (en) | Delayed-action form of administration containing tramadol saccharinate | |
| CN1419444A (en) | Pharmaceutical composition of topiramate | |
| CN1134108A (en) | Beads for controlled release and pharmaceutical preparation contg. same | |
| CN1886119A (en) | Pantoprazole multiparticulate formulations | |
| CN1090477C (en) | Ibuprofen-containing solid composition | |
| CN1008060B (en) | Process for preparation of theophylline sustained release formulation | |
| CN1883459A (en) | Enteric coated preparation of entecavir and preparation method thereof | |
| CN1839846A (en) | Levofloxacin slow release micropill, its preparation method and uses | |
| CN1267089C (en) | Morphine sulphate microgranules, method for preparing same and compositions containing same | |
| CN1110304C (en) | Controlled release pharmaceutical compositions for oral administration containing nifedipine as active substance | |
| CN1174505A (en) | Pharmaceutical composition comprising lamotrigine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |